Everence Capital Management Inc. Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Everence Capital Management Inc. acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 5,110 shares of the biopharmaceutical company’s stock, valued at approximately $244,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in HALO. Retirement Systems of Alabama raised its holdings in shares of Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after acquiring an additional 74,173 shares in the last quarter. Castellan Group increased its position in shares of Halozyme Therapeutics by 4.5% in the third quarter. Castellan Group now owns 113,798 shares of the biopharmaceutical company’s stock worth $6,514,000 after purchasing an additional 4,876 shares during the last quarter. Tidal Investments LLC raised its stake in Halozyme Therapeutics by 265.5% in the third quarter. Tidal Investments LLC now owns 20,576 shares of the biopharmaceutical company’s stock valued at $1,178,000 after purchasing an additional 14,947 shares in the last quarter. World Investment Advisors LLC bought a new stake in Halozyme Therapeutics during the third quarter valued at approximately $3,293,000. Finally, Sanctuary Advisors LLC lifted its position in Halozyme Therapeutics by 80.4% during the third quarter. Sanctuary Advisors LLC now owns 37,039 shares of the biopharmaceutical company’s stock valued at $2,120,000 after purchasing an additional 16,511 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 5.0 %

Shares of Halozyme Therapeutics stock opened at $53.76 on Thursday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company’s 50 day moving average price is $50.10 and its 200-day moving average price is $54.00. The stock has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a P/E/G ratio of 0.44 and a beta of 1.24.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HALO shares. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research report on Monday, December 30th. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Piper Sandler raised their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.